Abstract
Abstract Aspirin and other NSAIDs are widely used as analgesics and preventative agents for vascular events. Research evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. Data on the chemo preventative role of these drugs on the mortality in patients with upper aerodigestive tract cancer (UADT) are insufficient. The aim of this study was to investigate the effect of aspirin and other NSAIDs prescriptions after cancer diagnosis on the survival in UADT cancer patients. Patients with UADT cancer (oral cavity, oropharynx, hypopharynx, larynx or esophagus) were identified from the Primary Care Clinical Informatics Unit (PCCIU) database which contains information from a sample of general medical practices in Scotland, United Kingdom. Cox regression was used for statistical data analysis. There were 2,392 cases of UADT cancer diagnosed between 1996 and 2010 from 131 general medical practices. The mean age of patients was 66 years (SD 12), and most were male (63%). Median survival in head and neck cancer (HNC) patients was 94 months, while median survival in oesophageal cancer patients was 10 months. For HNC, improved survival was observed with aspirin prescription (ever vs never Hazard Ration (HR) = 0.5 95% Confidence Interval (CI) 0.4, 0.7) and other NSAIDs prescription (ever vs never HR = 0.7 95% CI 0.6, 0.9), however there was no association with COX-2 prescriptions. For oesophageal cancer patients, improved survival was observed with aspirin prescriptions (ever vs never HR = 0.5 95% CI 0.5, 0.6), Cox-2 prescriptions (HR = 0.8 95% CI 0.6, 0.9) and other NSAIDs (HR = 0.7 95% CI 0.6, 0.8). Conclusion: Aspirin and other NSAIDs prescriptions after diagnosis may reduce all-cause mortality in UADT cancer patients. Citation Format: Tatiana V. Macfarlane. Aspirin and other non-steroidal anti-inflammatory drug prescriptions after diagnosis and upper aerodigestive tract cancer survival. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2822. doi:10.1158/1538-7445.AM2015-2822
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
